Author

Abdul J. Sankoh

Observed names: A Sankoh, A. J. Sankoh, A. Sankoh, A.J. Sankoh, Abdul J Sankoh, Abdul Sankoh

Institution: Sage Therapeutics (United States)

Observed institutions: University of North Carolina at Chapel Hill, Northwell Health, UMass Memorial Health Care, United States Food and Drug Administration, Feinstein Institute for Medical Research, Center for Drug Evaluation and Research, University of Massachusetts Chan Medical School, Washington University in St. Louis, Sanofi (France), Atlanta Center for Medical Research, Synageva BioPharma (United States), Sage Therapeutics (United States), National Cancer Institute, UMass Memorial Medical Center, Zucker Hillside Hospital, Vertex Pharmaceuticals (United States), University of Pennsylvania

ORCID: 0009-0001-2618-0447

Observed ORCID: 0009-0001-2618-0447

OpenAlex ID: A5073452309

Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection

2011 · Ira M. Jacobson, John G. McHutchison, et al. · New England Journal of Medicine · 2,424

PDF

Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials

2018 · Samantha Meltzer-Brody, Helen Colquhoun, et al. · The Lancet · 818

Some comments on frequently used multiple endpoint adjustment methods in clinical trials

1997 · A. J. Sankoh, M. F. Huque, et al. · Statistics in Medicine · 810

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

2011 · Kenneth E. Sherman, Steven L. Flamm, et al. · New England Journal of Medicine · 745

PDF

Effect of Zuranolone vs Placebo in Postpartum Depression

2021 · Kristina M. Deligiannidis, Samantha Meltzer-Brody, et al. · JAMA Psychiatry · 297

PDF

Trial of SAGE-217 in Patients with Major Depressive Disorder

2019 · Handan Gunduz-Bruce, Christopher Silber, et al. · New England Journal of Medicine · 232

An Overview of Practical Approaches for Handling Missing Data in Clinical Trials

2009 · Cynthia M. DeSouza, Anna T. R. Legedza, et al. · Journal of Biopharmaceutical Statistics · 149

Multiple Co-primary Endpoints: Medical and Statistical Solutions: A Report from the Multiple Endpoints Expert Team of the Pharmaceutical Research and Manufacturers of America

2007 · Walter Offen, Christy Chuang-Stein, et al. · Drug Information Journal · 124

PDF

Efficacy endpoint selection and multiplicity adjustment methods in clinical trials with inherent multiple endpoint issues

2003 · Abdul J. Sankoh, Ralph B. D'Agostino, et al. · Statistics in Medicine · 111

Use of composite endpoints in clinical trials

2014 · Abdul J. Sankoh, Haihong Li, et al. · Statistics in Medicine · 79

Zuranolone in Major Depressive Disorder

2023 · Anita H. Clayton, Robert Lasser, et al. · The Journal of Clinical Psychiatry · 75

PDF

SAGE-217, A Novel GABAA Receptor Positive Allosteric Modulator: Clinical Pharmacology and Tolerability in Randomized Phase I Dose-Finding Studies

2019 · Ethan Hoffmann, George G. Nomikos, et al. · Clinical Pharmacokinetics · 59

PDF

The utility of mixed‐effects covariate analysis in rapid selection of doses in pediatric subjects: A case study with fexofenadine hydrochloride

2004 · Rajesh Krishna, Sriram Krishnaswami, et al. · Biopharmaceutics & Drug Disposition · 26

Patient-reported health-related quality of life from a randomized, placebo-controlled phase 2 trial of zuranolone in adults with major depressive disorder

2022 · Ellison Suthoff, Mark Kosinski, et al. · Journal of Affective Disorders · 24

PDF

A reviewer's perspective on multiple endpoint issues in clinical trials

1997 · M. F. Huque, A. J. Sankoh · Journal of Biopharmaceutical Statistics · 23

Global Two-Group Multiple Endpoint Adjustment Methods Applied to Clinical Trials

1999 · A. J. Sankoh, M. F. Huque, et al. · Drug Information Journal · 21

A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults

2021 · Amy Bullock, Handan Gunduz‐Bruce, et al. · Human Psychopharmacology Clinical and Experimental · 20

PDF

Composite and multicomponent end points in clinical trials

2017 · Abdul J. Sankoh, Haihong Li, et al. · Statistics in Medicine · 17

Interim Analyses: An Update of an FDA Reviewer’s Experience and Perspective

1999 · A. J. Sankoh · Drug Information Journal · 17

Dalzanemdor (SAGE‐718), a novel, investigational N‐methyl‐D‐aspartate receptor positive allosteric modulator: Safety, tolerability, and clinical pharmacology in randomized dose‐finding studies in healthy participants and an open‐label study in participants with Huntington's disease

2024 · Aaron Koenig, Michael Lewis, et al. · Clinical and Translational Science · 13

PDF

Extension of adaptive alpha allocation methods for strong control of the family‐wise error rate

2012 · Haihong Li, Abdul J. Sankoh, et al. · Statistics in Medicine · 10

A note on the conservativeness of the confidence interval approach for the selection of non‐inferiority margin in the two‐arm active‐control trial

2008 · Abdul J. Sankoh · Statistics in Medicine · 9

SAGE-217 in major depressive disorder: A multicenter, randomized, double-blind, Phase 2 placebo-controlled trial

2019 · H. Gunduz-Bruce, C. Silber, et al. · European Neuropsychopharmacology · 6

Interim Analyses: An FDA Reviewer's Experience and Perspective

1995 · A. J. Sankoh · Drug Information Journal · 6

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy of SAGE-217 in the Treatment of Adult Patients With Major Depressive Disorder

2020 · Anita Clayton, Robert Lasser, et al. · Biological Psychiatry · 5

Works count: 61

Citation count: 6,160

H-index: 17

I10-index: 21